Table 2 Relative risks of HHF and ESRD in SU group vs. DPP4i group (2nd cohort)
Study outcomes | Total | History of baseline HF | No history of baseline HF | ||||||
|---|---|---|---|---|---|---|---|---|---|
SU + MET (n = 4674) | DPP4i + MET (n = 9348) | P-value | SU + MET (n = 412) | DPP4i + MET (n = 824) | P-value | SU + MET (n = 4262) | DPP4i + MET (n = 8524) | P-value | |
HHF | |||||||||
 N. of events | 70 | 131 |  | 44 | 73 |  | 26 | 58 |  |
 Cumulative incidence at 3 years (%)a | 1.70 (1.30–2.23) | 2.20 (1.82–2.67) |  | 11.08 (8.00–15.26) | 13.40 (10.53–16.97) |  | 0.73 (0.47–1.15) | 1.09 (0.81–1.47) |  |
 HR (95% CI) at 3 yearsb | 1.00 | 1.39 (1.02–1.90) | 0.0369 | 1.00 | 1.29 (0.86–1.95) | 0.2250 | 1.00 | 1.61 (0.97–2.67) | 0.0634 |
 Cumulative incidence at 5 years (%)a | 2.97 (2.25–3.91) | 3.30 (2.46–4.44) |  | 19.96 (14.24–27.58) | 19.44 (12.38–29.79) |  | 1.21 (0.77–1.91) | 1.68 (1.15–2.45) |  |
 HR (95% CI) at 5 yearsb | 1.00 | 1.26 (0.95–1.67) | 0.1132 | 1.00 | 1.12 (0.77–1.64) | 0.5574 | 1.00 | 1.51 (0.96–2.39) | 0.0765 |
Study outcomes | Total | History of baseline HF | No history of baseline HF | ||||||
|---|---|---|---|---|---|---|---|---|---|
SU + MET (n = 4066) | DPP4i + MET (n = 7635) | P-value | SU + MET (n = 333) | DPP4i + MET (n = 613 | P | SU + MET (n = 3733) | DPP4i + MET (n = 7022) | P-value | |
ESRD eventsc | |||||||||
 N. of events | 11 | 17 |  | 2 | 4 |  | 9 | 13 |  |
 Cumulative incidence at 3 years (%)a | 0.34 (0.16–0.73) | 0.42 (0.25–0.70) |  | 0.00 | 1.23 (0.43–3.51) |  | 0.37 (0.17–0.81) | 0.35 (0.20–0.63) |  |
 HR (95% CI) at 3 yearsb | 1.00 | 1.55 (0.65–3.71) | 0.3255 |  | – |  | 1.00 | 1.17 (0.47–2.92) | 0.7298 |
 Cumulative incidence at 5 years (%)a | 0.77 (0.38–1.54) | 0.48 (0.29–0.80) |  | 1.81 (0.45–7.11) | 1.23 (043–3.51) |  | 0.67 (0.31–1.48) | 0.42 (0.23–0.75) |  |
 HR (95% CI) at 5 yearsb | 1.00 | 1.10 (0.54–2.28) | 0.7905 | 1.00 | 1.81 (0.45–7.11) | 0.3977 | 1.00 | 1.04 (0.46–2.35) | 0.9313 |